BriSTAR

BriSTAR Biopharma is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of innovative T-cell therapies for cancer. The company's core technology is the STAR-T (Synthetic T-cell Receptor and Antigen Receptor) platform, which combines the advantages of both CAR-T and TCR-T therapies to enhance sensitivity and persistence against tumors. BriSTAR's pipeline includes candidates targeting hematological malignancies and challenging solid tumors, such as hepatocellular carcinoma. By leveraging its proprietary platform, the company aims to overcome the limitations of current cell therapies, particularly in the treatment of solid cancers. The company has successfully advanced multiple programs into clinical trials, demonstrating the potential of its STAR-T technology in patients.